Clinical

Scholarly peer-reviewed articles reporting on factors associated with therapeutic inertia in caring for patients with hypertension were analyzed using scoping and bibliometric methods.

A recent review highlighted the importance of managing cardiovascular risk factors in patients with Fabry disease versus the general population.

Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.

The analysis showed biomarkers that persisted despite the presence or absence of type-2 inflammation.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss tracking their use of biosimilar by their providers and outcome measures they utilize to monitor biosimilars.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, recall what protocols and laws their organizations needed to abide by when transitioning to their biosimilars programs.

The authors identified consensus-based promoters of clinical inertia in managing hypertension. Policy makers should address these promoters to improve health-related outcomes in hypertension.

The parameter could potentially help clinicians zero in on the cause of left ventricular hypertrophy.

The American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium will feature presentations on oculofacial surgery innovations, social justice and diversity, and more.

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses the involvement of the JAK/STAT pathway in the pathogenesis of atopic dermatitis.

Most adverse events in trials of adenosine triphosphate (ATP) blockers for chronic cough are related to taste, which may inadvertently cause the studies to become unblinded to patients, and a way of measuring this to know the extent of the problem is needed, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

The American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) will be meeting in person in New Orleans to go over the latest scientific advances, said Robert G. Fante, MD, FACS, president of ASOPRS and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Older adults with coexisting asthma and chronic obstructive pulmonary disease (COPD), known as asthma-COPD overlap, who take fixed-dose combinations of inhaled corticosteroids and long-acting β agonists may be less likely to have persistent low adherence to initial maintenance therapy.

At the American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) 2021 Fall Scientific Symposium, Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica, will receive an award for his work on floppy eyelid syndrome and using collagen cross-linking to stiffen the eyelid and help patients.

A validation of the observer-reported outcome of the Growth Hormone Deficiency-Child Impact Measure found it valid and reliable to understand the impact of treatment with growth hormone therapy.

Daprodustat had no increased cardiovascular risk, compared with erythropoiesis stimulating agents (ESAs), in treating anemia in patients with chronic kidney disease (CKD) who were on dialysis and not on dialysis.

At baseline, patients with chronic thromboembolic pulmonary hypertension (CTEPH) had worse health-related quality of life (HRQOL) than patients with idiopathic pulmonary arterial hypertension (IPAH), but over time the scores were similar.

The higher waitlist mortality for liver transplant among children with hepatocellular carcinoma (HCC) compared with hepatoblastoma (HBL) indicates a need to improve prioritization for children with HCC.

Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, speaks on the symptom burden and current therapeutic interventions available for Fabry disease.

Baloxavir, compared with oseltamivir, was associated with lower health care resource utilization and costs in patients with influenza, particularly those at high risk of secondary complications.

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.

Several biomarkers identified by comprehensive genomic profiling were found to predict efficacy and toxicity of chemo-radiotherapy in patients with non–small cell lung cancer (NSCLC), with progression-free survival and overall survival outcomes associated with some of the identified genes.

Two experts examine how the biosimilar programs at their organization were created and the initial goals they had in mind.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the increased use of biosimilars, including successes and challenges and the process of transitioning to biosimilars at their organizations.

With no single biomarker for systemic lupus erythematosus, investigators wanted to investigate whether there is a connection between mean platelet volume and the disease.

Most early glucocorticoid treatment was targeted to patients with the most severe or active disease, according to study results from Canada.

As spinal muscular atrophy (SMA) treatments advance, new biomarkers that correlate with clinical outcomes are needed to gauge treatment response.

Multiple comorbidities and medications are prevalent in older cancer populations, who may benefit from structured medication reviews by specialist geriatricians.

Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.